Sichuan Hebang Biotechnology Corporation Limited (603077.SS)
CNY 1.69
(0.0%)
CNY 1.69
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.28 Billion CNY | -66.29% |
| 2022 | 3.8 Billion CNY | 26.12% |
| 2021 | 3.01 Billion CNY | 103643.84% |
| 2020 | 2.9 Million CNY | -99.44% |
| 2019 | 516.85 Million CNY | 42.35% |
| 2018 | 363.08 Million CNY | -29.84% |
| 2017 | 517.53 Million CNY | 62.85% |
| 2016 | 317.81 Million CNY | 32.5% |
| 2015 | 239.86 Million CNY | -64.29% |
| 2014 | 671.76 Million CNY | 942.51% |
| 2013 | 64.43 Million CNY | -80.76% |
| 2012 | 334.89 Million CNY | -8.57% |
| 2011 | 366.27 Million CNY | 111.97% |
| 2010 | 172.79 Million CNY | 291.33% |
| 2009 | 44.15 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 29.79 Million CNY | -88.72% |
| 2024 Q3 | 29.04 Million CNY | -82.12% |
| 2024 Q2 | 162.47 Million CNY | 445.36% |
| 2023 Q3 | 402.51 Million CNY | 82.98% |
| 2023 Q4 | 264.19 Million CNY | -34.36% |
| 2023 FY | 1.28 Billion CNY | -66.29% |
| 2023 Q1 | 396.56 Million CNY | 4.55% |
| 2023 Q2 | 219.97 Million CNY | -44.53% |
| 2022 Q2 | 1.59 Billion CNY | 52.67% |
| 2022 FY | 3.8 Billion CNY | 26.12% |
| 2022 Q4 | 379.3 Million CNY | -52.16% |
| 2022 Q1 | 1.04 Billion CNY | 3.25% |
| 2022 Q3 | 792.86 Million CNY | -50.19% |
| 2021 Q3 | 1.09 Billion CNY | 65.66% |
| 2021 Q4 | 1 Billion CNY | -8.11% |
| 2021 FY | 3.01 Billion CNY | 103643.84% |
| 2021 Q1 | 250.79 Million CNY | 4.58% |
| 2021 Q2 | 663.47 Million CNY | 164.55% |
| 2020 Q2 | 76.34 Million CNY | 343.72% |
| 2020 Q3 | -243.88 Million CNY | -419.44% |
| 2020 Q4 | 239.8 Million CNY | 198.33% |
| 2020 FY | 2.9 Million CNY | -99.44% |
| 2020 Q1 | -31.32 Million CNY | -160.34% |
| 2019 FY | 516.85 Million CNY | 42.35% |
| 2019 Q4 | 51.92 Million CNY | -68.98% |
| 2019 Q1 | 113.09 Million CNY | 232.5% |
| 2019 Q2 | 184.44 Million CNY | 63.1% |
| 2019 Q3 | 167.39 Million CNY | -9.25% |
| 2018 Q3 | 174.62 Million CNY | -22.04% |
| 2018 FY | 363.08 Million CNY | -29.84% |
| 2018 Q4 | -85.35 Million CNY | -148.88% |
| 2018 Q2 | 223.99 Million CNY | 349.71% |
| 2018 Q1 | 49.8 Million CNY | -71.26% |
| 2017 Q1 | 171.95 Million CNY | 29.88% |
| 2017 Q2 | 84.01 Million CNY | -51.14% |
| 2017 Q3 | 88.22 Million CNY | 5.02% |
| 2017 Q4 | 173.34 Million CNY | 96.47% |
| 2017 FY | 517.53 Million CNY | 62.85% |
| 2016 Q2 | 69.11 Million CNY | 28.95% |
| 2016 FY | 317.81 Million CNY | 32.5% |
| 2016 Q4 | 132.39 Million CNY | 111.17% |
| 2016 Q1 | 53.6 Million CNY | -28.14% |
| 2016 Q3 | 62.69 Million CNY | -9.29% |
| 2015 Q2 | 98.4 Million CNY | 157.28% |
| 2015 Q4 | 74.59 Million CNY | 160.59% |
| 2015 Q3 | 28.62 Million CNY | -70.91% |
| 2015 Q1 | 38.24 Million CNY | 281.73% |
| 2015 FY | 239.86 Million CNY | -64.29% |
| 2014 FY | 671.76 Million CNY | 942.51% |
| 2014 Q3 | 19.5 Million CNY | -96.96% |
| 2014 Q1 | 31.04 Million CNY | 38.62% |
| 2014 Q4 | -21.04 Million CNY | -207.88% |
| 2014 Q2 | 642.25 Million CNY | 1968.49% |
| 2013 FY | 64.43 Million CNY | -80.76% |
| 2013 Q2 | 330.56 Thousand CNY | -99.19% |
| 2013 Q3 | 694.39 Thousand CNY | 110.06% |
| 2013 Q1 | 41.01 Million CNY | 182.62% |
| 2013 Q4 | 22.39 Million CNY | 3125.73% |
| 2012 Q2 | 129.16 Million CNY | -7.39% |
| 2012 Q4 | 14.51 Million CNY | -71.96% |
| 2012 Q1 | 139.46 Million CNY | 64.15% |
| 2012 Q3 | 51.75 Million CNY | -59.93% |
| 2012 FY | 334.89 Million CNY | -8.57% |
| 2011 FY | 366.27 Million CNY | 111.97% |
| 2011 Q3 | 154.84 Million CNY | 0.0% |
| 2011 Q4 | 84.96 Million CNY | -45.13% |
| 2010 FY | 172.79 Million CNY | 291.33% |
| 2009 FY | 44.15 Million CNY | 0.0% |